ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $30.00 price objective on the stock.

Several other equities analysts have also recently weighed in on the company. BTIG Research began coverage on ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Stock Up 3.0 %

IBRX opened at $2.39 on Thursday. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The firm has a 50 day moving average price of $3.84 and a 200-day moving average price of $4.27. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -2.60 and a beta of 0.86.

Institutional Investors Weigh In On ImmunityBio

Hedge funds have recently modified their holdings of the business. Captrust Financial Advisors bought a new position in ImmunityBio in the 3rd quarter worth $41,000. Algert Global LLC purchased a new stake in ImmunityBio in the second quarter worth about $86,000. Virtu Financial LLC bought a new position in shares of ImmunityBio in the third quarter worth about $51,000. Dimensional Fund Advisors LP purchased a new position in shares of ImmunityBio during the 2nd quarter valued at about $105,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of ImmunityBio during the 2nd quarter valued at approximately $126,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.